UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients

Annals of oncology, 2019-02, Vol.30 (2), p.259-265

2019

Volltextzugriff (PDF)

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

Annals of oncology, 2018-03, Vol.29 (3), p.624-631

2018

Volltextzugriff (PDF)

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study

Annals of oncology, 2015-07, Vol.26 (7), p.1427-1433

2015

Volltextzugriff (PDF)

Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912

Annals of oncology, 2013-10, Vol.24 (10), p.2560-2565

2013

Volltextzugriff (PDF)

A multicentre, prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancer

Annals of oncology, 2018-06, Vol.29, p.v101-v102

2018

Volltextzugriff (PDF)

Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii159

2018

Volltextzugriff (PDF)

REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis

Annals of oncology, 2018-06, Vol.29, p.v95-v95

2018

Volltextzugriff (PDF)

A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study

Annals of oncology, 2018-06, Vol.29, p.v71-v71

2018

Volltextzugriff (PDF)

A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii162

2018

Volltextzugriff (PDF)

A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients

Japanese journal of clinical oncology, 2013-11, Vol.43 (11), p.1080-1086

2013

Volltextzugriff (PDF)

The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer

Annals of oncology, 2017-09, Vol.28, p.v192-v192

2017

Volltextzugriff (PDF)

Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis

ESMO Gastrointestinal Oncology, 2023-12, Vol.2, p.100008, Article 100008

2023

Volltextzugriff (PDF)

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)

ESMO open, 2022-12, Vol.7 (6), p.100592, Article 100592

2022

Volltextzugriff (PDF)

Functional separation in two frequency operation of an inductively coupled plasma

Journal of applied physics, 2004-02, Vol.95 (3), p.870-876

2004

Volltextzugriff (PDF)

2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC)

European journal of cancer (1990), 2015-09, Vol.51, p.S383-S384

2015

Volltextzugriff (PDF)

2158 The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): Simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01)

European journal of cancer (1990), 2015-09, Vol.51, p.S386-S386

2015

Volltextzugriff (PDF)

2168 Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study

European journal of cancer (1990), 2015-09, Vol.51, p.S389-S390

2015

Volltextzugriff (PDF)

Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study

Annals of oncology, 2012-04, Vol.23 (4), p.933-941

2012

Volltextzugriff (PDF)

6107 POSTER Improved Overall Survival in the Patients With Metastatic Colorectal Cancer Associated With Ant-VEGF Antibody Drug and Anti-EGFR Antibody Drug Administration

European journal of cancer (1990), 2011, Vol.47, p.S424-S424

2011

Volltextzugriff (PDF)

6118 POSTER Randomized Phase II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) Versus MFOLFOX6 in Patients With Untreated Metastatic Colorectal Cancer (mCRC)

European journal of cancer (1990), 2011, Vol.47, p.S427-S428

2011

Volltextzugriff (PDF)

1142 POSTER Clinical Significance of Macrodissection in Two Different KRAS Tests for Colorectal Cancer: Results From a Multi-center Clinical Trial

European journal of cancer (1990), 2011, Vol.47, p.S136-S137

2011

Volltextzugriff (PDF)

6586 POSTER Metronomic Combination Chemotherapy With S-1 and Biweekly Paclitaxel for Advanced Gastric Cancer

European journal of cancer (1990), 2011, Vol.47, p.S467-S467

2011

Volltextzugriff (PDF)

Expansion of metallic mesh stent hole using a Soehendra stent retriever in multiple stenting of biliary hilar obstruction

Endoscopy, 2008-09, Vol.40 Suppl 2 (S 02), p.E147-E148

2008

Volltextzugriff (PDF)

Hybrid origins of Ixeris nakazonei (Asteraceae, Lactuceae) in the Ryukyu Archipelago, Japan: evidence from molecular data

Botanical journal of the Linnean Society, 2003-03, Vol.141 (3), p.379-387

2003

Volltextzugriff (PDF)

1 – 25 von 1.570

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.105)
Mit Volltextzugriff
(1.252)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study

Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912

A multicentre, prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancer

Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer

REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis

A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study

A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3

A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients

The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer

Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)

Functional separation in two frequency operation of an inductively coupled plasma

2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC)

2158 The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): Simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01)

2168 Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study

Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study

6107 POSTER Improved Overall Survival in the Patients With Metastatic Colorectal Cancer Associated With Ant-VEGF Antibody Drug and Anti-EGFR Antibody Drug Administration

6118 POSTER Randomized Phase II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) Versus MFOLFOX6 in Patients With Untreated Metastatic Colorectal Cancer (mCRC)

1142 POSTER Clinical Significance of Macrodissection in Two Different KRAS Tests for Colorectal Cancer: Results From a Multi-center Clinical Trial

6586 POSTER Metronomic Combination Chemotherapy With S-1 and Biweekly Paclitaxel for Advanced Gastric Cancer

Expansion of metallic mesh stent hole using a Soehendra stent retriever in multiple stenting of biliary hilar obstruction

Hybrid origins of Ixeris nakazonei (Asteraceae, Lactuceae) in the Ryukyu Archipelago, Japan: evidence from molecular data

Suchergebnisse filtern